CurrentEndo — Pituitary & hypothalamus

A hypodiploid corticotroph pituitary tumor with a germline TP53 variant

2026-11-14T19:45:37.010Z

Research article · Eur J Endocrinol, 2026.

Evaluation of voice features using Wav2vec2.0-based deep learning as a diagnostic tool in acromegaly

2026-11-14T10:46:26.825Z

Diagnostic or prognostic study · Pituitary, 2026.

Posterior pituitary tumors: review of histogenetic continuum, molecular drivers and targetable therapies

2026-11-14T10:46:26.825Z

Research article · Pituitary, 2026.

Risk factors for postoperative hyponatremia after endoscopic endonasal surgery for nonfunctioning pituitary adenoma

2026-11-14T10:46:26.825Z

Research article · Pituitary, 2026.

Trigeminal autonomic cephalgia due to pituitary adenomas: scoping review of the literature

2026-11-14T10:46:26.825Z

Research article · Pituitary, 2026.

Upper limb arthropathy in acromegaly: Radiological findings and functional impairment

2026-11-14T10:46:26.825Z

Cohort study · Pituitary, 2026.

Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study

2026-11-13T19:45:41.967Z

Cohort study · J Clin Endocrinol Metab, 2026.

Long-Term Changes in the Size of Pituitary Microadenomas

2026-11-13T11:01:36.927Z

Cohort study · Ann Intern Med, 2023. Change in microadenoma size (patients with >1 MRI): No change in size 78

A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

2026-11-13T10:09:36.510Z

Research article · Pituitary, 2022. IGF-I control with EDIs: Maintenance of normal IGF-I in ≥ 70% of patients with LAN (1 study), OCT (1 study) and pegvisomant monotherapy (1 study)

Delayed postoperative hyponatremia in patients with acromegaly: incidence and predictive factors

2026-11-13T10:09:36.510Z

Cohort study · Pituitary, 2022. Incidence of DPH: DPH occurred 39 patients (41.5%)

Gigantism: microsurgical treatment by transsphenoidal approach and prognostic factors

2026-11-13T10:09:36.510Z

Cohort study · Pituitary, 2022. Postoperative hormone levels achieving disease control criteria: Patients achieving disease control criteria postoperatively 6 (42.8%)

Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis

2026-11-13T10:09:36.510Z

Research article · Pituitary, 2023. Hormone responses to OGTT by treatment regimen — SSA; P = 0.001; impaired GIP-response (AUC)

IGF-1 is positively associated with BMI in patients with acromegaly

2026-11-13T10:09:36.510Z

Cohort study · Pituitary, 2023. Association between BMI and %ULN IGF-1: Acromegaly: significant positive association between BMI and %ULN IGF-1 (p < 0.05) R = 0.35

Machine learning models predict delayed hyponatremia post-transsphenoidal surgery using clinically available features

2026-11-13T10:09:36.510Z

Cohort study · Pituitary, 2023. ROC-AUC for DHN prediction: RF 0.759 ± 0.039; AUC 0.759 ± 0.039 · Support vector machine 0.747 ± 0.034; AUC 0.747 ± 0.034 · LGBM 0.738 ± 0.026; AUC 0.738 ± 0.026 · Logistic regression 0.710 ± 0.028; AUC 0.710 ± 0.028

Pituitary enlargement in patients with cerebrospinal fluid drainage due to ventricular shunt insertion: know the condition and do not mistake for adenoma

2026-11-13T10:09:36.510Z

Cohort study · Pituitary, 2023. Both hydrocephalus groups vs Population mean: t (midsagittal size) 5.91; p < 0.001; significantly higher in hydrocephalus groups

Post-operative surveillance for somatotroph, lactotroph and non-functional pituitary adenomas after curative resection: a systematic review

2026-11-13T10:09:36.510Z

Meta-analysis · Pituitary, 2022. Recurrence rate, 1 year / 5 years / 10 years: NFPA 1%, 17%, 33%; 1 year 1%; 5 years 17%; 10 years 33% · PSPA 6%, 21%, 28%; 1 year 6%; 5 years 21%; 10 years 28% · GHPA 3%, 8%, 13%; 1 year 3%; 5 years 8%; 10 years 13%

Posterior hypothalamic involvement on pre-operative MRI predicts hypothalamic obesity in craniopharyngiomas

2026-11-13T10:09:36.510Z

Cohort study · Pituitary, 2022. Post-operative BMI — Ant and post HI vs No HI or anterior HI only; p < 0.01; higher with ant and post HI on pre-operative MRI

Predicting tumor consistency and extent of resection in non-functioning pituitary tumors

2026-11-13T10:09:36.510Z

Diagnostic or prognostic study · Pituitary, 2023. NFPT consistency (CP): T2SIR: AUC 0.88

Reported outcomes in transsphenoidal surgery for pituitary adenomas: a systematic review

2026-11-13T10:09:36.510Z

Meta-analysis · Pituitary, 2023. Outcome domains reported (studies): Surgical complications (most reported) n = 116, 65%

Role of biological effective dose for prediction of endocrine remission in acromegaly patients treated with stereotactic radiosurgery

2026-11-13T10:09:36.510Z

Cohort study · Pituitary, 2022. Endocrine remission: Cumulative probability of maintained endocrine remission off suppressive medications at 3 years 62.5% [47.9-73.0]

Serum biomarkers of colonic polyps in patients with acromegaly: a meta-analysis and systematic review

2026-11-13T10:09:36.510Z

Meta-analysis · Pituitary, 2022. Serum biomarker levels (meta-analysis) — Colonic polyps vs No colonic polyps: SMD (IGF-1 × ULN) 0.23 (95% CI 0.03-0.42); p < 0.05; higher with colonic polyps

UK practice on incidentally detected non-functioning pituitary microadenomas: analysis of two national surveys during a 12-year interval

2026-11-13T10:09:36.510Z

Cross-sectional study · Pituitary, 2022. Baseline biochemical investigations: 2021 survey 96.0%; IGF-1 measured 96.0%; morning cortisol 87.9%; GH 26.2%; 24 h UFC 3.4%; dynamic adrenal reserve assessment 11.4% · 2009 survey 74.1%; IGF-1 measured 74.1%; morning cortisol 62.6%; GH 42.6%; 24 h UFC 23.2%; dynamic adrenal reserve assessment 30.4%

Severe Obesity Associated With Pituitary Corticotroph Hyperplasia and Neoplasia

2026-11-13T10:04:31.875Z

Cohort study · Endocr Pract, 2023. Pituitary CH/neoplasia: Lean 4 (9.1%) · Overweight 12 (27.3%) · Obesity class I 10 (22.7%) · Obesity classes II to III 18 (40.9%)

Should We Use Prolactin Adjustment in Bilateral Inferior Petrosal Sinus Sampling to Diagnose Cushing Disease? A Joint Meta-Analysis of Head-to-Head Diagnostic Tests Accuracy Studies

2026-11-13T10:04:31.875Z

Meta-analysis · Endocr Pract, 2023. Prolactin adjustment: sensitivity 99.97% (95% CI, 99.03%-100.00%); specificity 80.69% (95% CI, 50.27%-97.82%) · No adjustment: sensitivity 94.47% (95% CI, 88.67%-98.44%); specificity 91.14% (95% CI, 57.17%-99.80%)

Arginine‐stimulated copeptin in children and adolescents

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. Copeptin in non-AVPD patients: Baseline copeptin range, non-AVPD 1.3-44.4 pmol/L

High prevalence of coronary artery calcification and increased risk for coronary artery disease in patients with Sheehan syndrome—A case–control study

2026-11-13T09:59:57.591Z

Case-control study · Clin Endocrinol (Oxf), 2022. coronary artery calcium (CAC) detected: SS 50.7% · Controls 7.6%

Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. Tumour size change during observation, mean follow-up 4.9 ± 4.9 years: Increase in tumour size 16 patients (33%)

Sex difference in patients with controlled acromegaly—A multicentre survey

2026-11-13T09:59:57.591Z

Cross-sectional study · Clin Endocrinol (Oxf), 2022. Disease control by fasting growth hormone (GH) < 1.0 µg/L: F 56% · M 83%

The clinical and metabolic characteristics of children and adolescents with hypothalamic dysfunction: A single‐centre study from China

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. Intracranial tumour (most common aetiology, especially germ cell tumours) 37.5%

The effect of mindfulness therapy in acromegaly, a pilot study

2026-11-13T09:59:57.591Z

Randomized controlled trial · Clin Endocrinol (Oxf), 2022. Changes in QoL, mood, pain, sleep, self-compassion, life satisfaction, blood pressure and heart rate after program: BCN intervention: increase in night-time hours in bed after program p = 0.05

Adrenocortical, somatotropic, and antidiuretic response to nasal glucagon in healthy subjects

2026-11-13T09:58:18.729Z

Randomized controlled trial · Eur J Endocrinol, 2023. Corticotropic, somatotropic and antidiuretic axis response: Adrenocorticotropic hormone (ACTH) and cortisol decreased progressively after both glucagon and placebo P < 0.001

C-peptide level concomitant with hypoglycemia gives better performances than insulin for the diagnosis of endogenous hyperinsulinism: a single-center study of 159 fasting trials

2026-11-13T09:58:18.729Z

Diagnostic or prognostic study · Eur J Endocrinol, 2023. Diagnostic performance (ROC) for endogenous hyperinsulinism, fasting trial: Glycemia nadir: cutoff 2.3 mmol/L; sensitivity 100%; specificity 81% · Insulin: cutoff 3.1 mUI/L; sensitivity 96%; specificity 92% · C-peptide: cutoff 0.30 nmol/L; sensitivity 96%; specificity 100%

Copeptin improves prediction of treatment response in children with monosymptomatic nocturnal enuresis

2026-11-13T09:58:18.729Z

Cohort study · Eur J Endocrinol, 2023. Prediction of treatment response by baseline copeptin ratio, 12 weeks: Best copeptin ratio cutoff 1.34

Diagnostic criteria for the hypothalamic syndrome in childhood

2026-11-13T09:58:18.729Z

Diagnostic or prognostic study · Eur J Endocrinol, 2023. hypothalamic syndrome (HS) by new hypothalamic score: Scored as having HS 52.5%

Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment

2026-11-13T09:58:18.729Z

Cohort study · Eur J Endocrinol, 2023. Change after treatment: body composition, intrahepatic lipid and HOMA-IR: Acromegaly: disease control decreased lean body mass P < .000

Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in acromegaly

2026-11-13T09:58:18.729Z

Mechanistic study · Eur J Endocrinol, 2023. SAT gene expression before vs after disease control: Genes significantly differentially expressed (P-adjusted < .05) 743

Overcorrection and undercorrection with fixed dosing of bolus hypertonic saline for symptomatic hyponatremia

2026-11-13T09:58:18.729Z

Cohort study · Eur J Endocrinol, 2023. Overcorrection 32 patients (18%)

Pregnancy-related hypophysitis revisited

2026-11-13T09:58:18.729Z

Cohort study · Eur J Endocrinol, 2023. Distinguishing features of PR-Hy vs non-PR-Hy — PR-Hy vs non-PR-Hy: chiasmal syndrome; P < .0001; 50% vs 13%

Real-time detection of acromegaly from facial images with artificial intelligence

2026-11-13T09:58:18.729Z

Diagnostic or prognostic study · Eur J Endocrinol, 2023. Detection of acromegaly from facial images: ResNet50: PPV 0.958 · DenseNet121: PPV 0.965 · InceptionV3: PPV 0.962 · EM: PPV 0.997; sensitivity 0.997; specificity 0.997; accuracy 0.997; precision 0.998

Obesity, Overweight, and Pituitary Stalk Interruption Syndrome in Children and Young Adults

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. History of neonatal hypoglycemia: OB-OW 57% · NO 14%

Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands

2026-11-13T09:55:31.327Z

Cross-sectional study · J Clin Endocrinol Metab, 2022. Factors associated with resistance to first-generation SRL (fg-SRL): Low survivin expression associated with fg-SRL resistance P = 0.04

Treatment of Cushing Disease With Pituitary-Targeting Seliciclib

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. UFC normalization or ≥ 50% UFC reduction, study end: Patients achieving ≥ 50% UFC reduction (range, 55%-75%) 3

Diagnostic Accuracy of Morning Salivary Cortisol in the Assessment of the Hypothalamic-Pituitary-Adrenal Axis Recovery after Prolonged Corticosteroid Therapy in Children

2026-11-13T04:57:29.624Z

Diagnostic or prognostic study · Horm Res Paediatr, 2023. Diagnostic accuracy of mSAF for HPA recovery vs serum cortisol reference, 48 h after cessation of glucocorticoid therapy: ROC cut-off for mSAF ≥5.0 nmol/L

Schaaf-Yang Syndrome: Clinical Phenotype and Effects of 4 years of Growth Hormone Treatment

2026-11-13T04:57:29.624Z

Cohort study · Horm Res Paediatr, 2023. Height SDS, start to 4 years of GH: GH mean -0.05 (95% CI -1.87; 1.77) SDS; baseline mean (95% CI) -1.74 (-3.55; 0.07)

Antiplatelet and anticoagulation therapy and the risk of pituitary apoplexy in pituitary adenoma patients

2026-11-13T04:56:40.988Z

Cohort study · Pituitary, 2023. AP/AC use in patients with vs without apoplexy — No apoplexy vs Apoplexy; p = 0.5; aspirin: 45 no apoplexy vs. 10 apoplexy; no significant difference

Characteristics of inflammatory and infectious diseases of the pituitary gland in patients undergoing transsphenoidal surgery

2026-11-13T04:56:40.988Z

Cohort study · Pituitary, 2023. Histopathology of IIPD: Septic infection 10 cases

Clinical and imaging findings for the evaluation of large Rathke’s cleft cysts and cystic craniopharyngiomas

2026-11-13T04:56:40.988Z

Cohort study · Pituitary, 2023. Clinical and MR imaging findings: Age of onset, LRCCs vs CCPs (years) 49.0 ± 16.8 vs 34.2 ± 22.2; p = .022

Differences in clinical, hormonal, and radiological presentation and in surgical outcomes in patients presenting with and without pituitary apoplexy. A multicenter study of 245 cases

2026-11-13T04:56:40.988Z

Cohort study · Pituitary, 2023. Clinical, hormonal and radiological presentation — Apoplexy vs Non-pituitary apoplexy: Men; p = 0.003; 70% vs 48.1%

Efficacy and safety of cavernous sinus medial wall resection in pituitary adenoma surgery: a systematic review and a single-arm meta-analysis

2026-11-13T04:56:40.988Z

Meta-analysis · Pituitary, 2023. Pooled proportion of endocrinological remission (ER): Pooled proportion of ER 63.3%

Importance of 24 h ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings

2026-11-13T04:56:40.988Z

Cross-sectional study · Pituitary, 2023. Arterial hypertension by 24 h-ABPM vs OBP: Non-hypertensive by OBP with AH on 24 h-ABPM 9 of 29